STOCK TITAN
  1. Home
  2. Sec-filings
  3. AAPG
  4. [Form 3/A] ASCENTAGE PHARMA GROUP INTERNATIONAL Amended Initial Statement of Beneficial Ownership

Ascentage Pharma (AAPG) director corrects and details option and RSU stakes

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
3/A

Rhea-AI Filing Summary

ASCENTAGE PHARMA GROUP INTERNATIONAL director Ye Changqing filed an amended initial ownership report that corrects and clarifies his equity holdings. The filing shows options over 18,850 Ordinary Shares at an exercise price of $8.14 expiring on November 26, 2035, 28,850 restricted share units that vest in four equal annual installments from November 26, 2026 through 2029, and 8,964 Ordinary Shares held directly. Footnotes explain that the numbers of Ordinary Shares, share options, and vesting schedules were inadvertently reported incorrectly in the original submission.

Positive

  • None.

Negative

  • None.
Insider Ye Changqing
Role Director
Type Security Shares Price Value
holding Options -- -- --
holding Restricted share units -- -- --
holding Ordinary Shares -- -- --
Holdings After Transaction: Options — 18,850 shares (Direct); Restricted share units — 28,850 shares (Direct); Ordinary Shares — 8,964 shares (Direct)
Footnotes (1)
  1. The number of Ordinary Shares were inadvertently not reported in the original submission. The stock options vest in twelve (12) tranches equally on the 26th of the month starting November 26, 2025. The exercise price for the stock options is in HKD, and the exercise price included in the table represents conversion to USD based on the exchange rate on the date of grant. Each restricted stock unit (RSUs) represents a contingent right to receive one Ordinary Share of the Issuer upon vesting. The RSUs vest in four equal increments on each of 11/26/2026, 2027, 2028 and 2029. The number of Share Options and/or vesting were inadvertently incorrectly reported in the original submission.
Understanding Insider Trading Forms →
SEC Form 3
FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0104
Estimated average burden
hours per response:0.5
1. Name and Address of Reporting Person*
Ye Changqing
(Last)(First)(Middle)
700 KING FARM BLVD
STE 510
(Street)
ROCKVILLE MARYLAND 20850
(City)(State)(Zip)
UNITED STATES
(Country)		2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026		3. Issuer Name and Ticker or Trading Symbol
ASCENTAGE PHARMA GROUP INTERNATIONAL [ AAPG ]
3a. Foreign Trading Symbol
5. If Amendment, Date of Original Filed (Month/Day/Year)
03/19/2026
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares(1)8,964(1)D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Options (2)11/26/2035Ordinary Shares18,850(5)$8.14(3)D
Restricted share units (4) (4)Ordinary Shares28,850$0D
Explanation of Responses:
1. The number of Ordinary Shares were inadvertently not reported in the original submission.
2. The stock options vest in twelve (12) tranches equally on the 26th of the month starting November 26, 2025.
3. The exercise price for the stock options is in HKD, and the exercise price included in the table represents conversion to USD based on the exchange rate on the date of grant.
4. Each restricted stock unit (RSUs) represents a contingent right to receive one Ordinary Share of the Issuer upon vesting. The RSUs vest in four equal increments on each of 11/26/2026, 2027, 2028 and 2029.
5. The number of Share Options and/or vesting were inadvertently incorrectly reported in the original submission.
Remarks:
/Chnagqing Ye/03/23/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR